MOG and myeloid sarcoma: The development of an assay to detect antibodies against natively-folded MOG was a breakthrough that led to the determination of MOG-IgG positivity in approximately 20% of patients with acute disseminated encephalomyelitis (ADEM), compared to only 1% of patients from North America with adult-onset MS (54).